Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II

Cancer Letters

Volumn 206, Issue 1, 2004, Pages 85-96

  Lund, Per ^a   Schubert, Dominic ^a   Niketeghad, Fataneh ^a   Schirmacher, Peter ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Apoptosis; Chemotherapy; Hepatocellular carcinoma; IGF I receptor; Insulin like growth factors

Indexed keywords

CISPLATIN; ETOPOSIDE; SOMATOMEDIN B;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CELL DEATH; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; LIVER TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; STATISTICAL SIGNIFICANCE; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOCRINE COMMUNICATION; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CISPLATIN; ETOPOSIDE; HUMANS; IN SITU NICK-END LABELING; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 1442359894     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.10.018     Document Type: Article

References (44)

1. Bressac B., Galvin K.M., Liang T.J., Isselbacher K.J., Wands J.R., Ozturk M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc. Natl Acad. Sci. USA. 87:1990;1973-1977.
2. Murakami Y., Hayashi K., Hirohashi S., Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 51:1991;5520-5525.
3. D'Errico A., Fiorentino M., Ponzetto A., Daikuhara Y., Tsubouchi H., Brechot C., et al. Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: its specific receptor c-met does. Hepatology. 24:1996;60-64.
4. de La Coste A., Romagnolo B., Billuart P., Renard C.A., Buendia M.A., Soubrane O., et al. Somatic mutations of beta catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl Acad. Sci. USA. 95:1998;8847-8851.
5. Yamaguchi K., Carr B.I., Nalesnik M.A. Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine and endocrine growth of human hepatoma. J. Surg. Oncol. 58:1998;240-245.
6. Nielsen F.C. The molecular and cellular biology of insulin-like growth factor II. Prog. Growth Factor Res. 4:1993;257-290.
7. Okamoto T., Nishimoto I., Murayama Y., Ohkuni Y., Ogata E. Insulin-like growth factor-II/mannose 6-phosphate receptor is incapable of activating GTP-binding proteins in response to mannos 6-phosphate, but capable in response to insulin-like growth factor-II. Biochem. Biophys. Res. Commun. 168:1990;1201-1210.
8. Auletta M., Nielsen F.C., Gammeltoft S. Receptor-mediated endocytosis and degradation of insulin-like growth factor I and II in neonatal rat astrocytes. J. Neurosci. Res. 31:1992;14-20.
9. Ullrich A., Gray A., Tam A.W., Yang-Feng T., Tsubokawa M., Collins C., et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. Eur. Mol. Biol. Org. J. 5:1986;2503-2512.
10. Morgan D.O., Jarnagin K., Roth R.A. Purification and characterization of the receptor for insulin-like growth factor I. Biochemistry. 25:1986;5560-5564.
11. Li X., Cui H., Sandstedt B., Nordlinder H., Larsson E., Ekström T.J. Expression levels of the insulin-like growth factor-II gene (IGF-II) in the human liver: developmental relationships of the four promoters. J. Endocrinol. 149:1996;117-124.
12. Li X., Ekström C., Larsson E., Nordlinder H., Hofmann W.J., Trautwein C., et al. Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res. 57:1997;2048-2054.
13. Fu X.X., Su C.Y., Lee Y., Hintz R., Biempica L., Snyder R., Rogler C.E. Insulin-like growth factor II expression and oval cell proliferation associated with hepatocarcinogenesis in woodchuck hepatitis virus carriers. J. Virol. 62:1988;3422-3430.
14. Ueno T., Takahashi K., Matsuguchi T., Ikejiri K., Endo H., Yamamoto M. Reactivation of rat insulin-like growth factor II during hepatocarcinogenesis. Carcinogenesis. 9:1988;1779-1783.
15. Schirmacher P., Held W.A., Yang D., Chisari F.V., Rustum Y., Rogler C.E. Reactivation of insulin-like growth factor during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res. 52:1992;2549-2556.
16. Zhang N., Siegel K., Odenthal M., Becker R., Oesch F., Dienes H.P., et al. The role of insulin-like growth factor II in the malignant transformation of rat liver oval cells. Hepatology. 25:1997;900-905.
17. De Souza A.T., Hankins G.R., Washington M.K., Orton T.C., Jirtle R.L. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat. Genet. 11:1995;447-449.
18. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B.R., Kley N. Induction of growth inhibitor IGF-binding protein 3 by p53. Nature. 377:1995;646-649.
19. Christofori G., Naik P., Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature. 369:1994;414-417.
20. Rogler C.E., Yang D., Rossetti L., Donohoe J., Alt E., Chang C.J., et al. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J. Biol. Chem. 269:1994;13779-13784.
21. Kiess W., Koepf G., Christiansen H., Blum W.F. Human neuroblastoma cells use either insulin-like growth factor-I or insulin-like growth factor-II in an autocrine pathway via the IGF-I receptor: variability of IGF, IGF binding protein (IGFBP) and IGF receptor gene expression and IGF and IGFBP secretion in human neuroblastoma cells in relation to cellular proliferation. Regul. Pept. 72:1997;19-29.
22. Qing R.Q., Schmitt S., Ruelicke T., Stallmach T., Schoenle E.J. Autocrine regulation of growth by insulin-like growth factor (IGF)-II mediated by type I IGF-receptor in Wilms tumor cells. Pediatr. Res. 39:1996;160-165.
23. Minniti C.P., Luan D., O'Grady C., Rosenfeld R., Oh Y., Helman L.J. Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. Cell Growth Differ. 6:1995;263-269.
24. Zhang L., Zhou W., Velculescu V.E., Kern S.E., Hruban R.H., Hamilton S.R., et al. Gene expression profiles in normal and cancer cells. Science. 276:1997;1268-1272.
25. Christofori G., Naik P., Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature. 369:1994;414-418.
26. Lamm G.M., Christofori G. Impairment of survival factor function potentiates chemotherapy-induced apoptosis in tumor cells. Cancer Res. 58:1998;801-807.
27. Xu F., Gardner A., Tu Y., Michl P., Prager D., Lichtenstein A. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br. J. Haematol. 97:1997;429-440.
28. Mooney A., Jobson T., Bacon R., Kitamura M., Savill J. Cytokines promote glomerular mesangial cell survival in vitro by stimulus-dependent inhibition of apoptosis. J. Immunol. 159:1997;3949-3959.
29. Resnicoff M., Abraham D., Yutanawiboonchai W., Rotman H.L., Kajstura J., Rubin R., et al. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 55:1995;2463-2469.
30. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. 55:1995;249-252.
31. Sell C., Baserga R., Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I-receptor prevent etoposide-induced apoptosis. Cancer Res. 55:1995;303-306.
32. Sullivan K.A., Castle V.P., Hanash S.M., Feldman E.L. Insulin-like growth factor II in the pathogenesis of human neuroblastoma. Am. J. Pathol. 147:1995;1790-1798.
33. Takanami I., Imamuma T., Hashizume T., Kikuchi K., Yamamoto Y., Yamamoto T., Kodaira S. Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma. J. Surg. Oncol. 61:1996;205-208.
34. Fiorentino M., Grigioni W.F., Baccarini P., D'Errico A., De Mitri M.S., Pisi E., Mancini A.M. Different in situ expression of insulin-like growth factor type II in hepatocellular carcinoma, An in situ hybridization and immunohistochemical study. Diagn. Mol. Pathol. 3:1994;59-65.
35. Zvibel I., Brill S., Reid L.M. Insulin-like growth factor II regulation of gene expression in rat and human hepatomas. J. Cell Physiol. 162:1995;36-43.
36. Yang D., Faris R., Hixson D., Affigne S., Rogler C.E. Insulin-like growth factor II blocks apoptosis of N-myc2-expressing woodchuck liver epithelial cells. J. Virol. 70:1996;6260-6268.
37. Harrington E.A., Bennett M.R., Fanidi A., Evan G.I. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. Eur. Mol. Biol. Org. J. 13:1994;3286-3295.
38. Hague A., Hicks D.J., Bracey T.S., Paraskeva C. Cell-cell contact and specific cytokines inhibit apoptosis of colonic epithelial cells: growth factors protect against c-myc-independent apoptosis. Br. J. Cancer. 75:1997;960-968.
39. Stewart C.E., Rotwein P. Insulin-like growth factor-II is an autocrine survival factor for differentiating myoblasts. J. Biol. Chem. 271:1996;11330-11338.
40. Hill P.A., Tumber A., Meikle M.C. Multiple extracellular signals promote osteoblast survival and apoptosis. Endocrinology. 138:1997;3849-3858.
41. Desai B.J., Gruber H.E. Anti-apoptotic actions of cytokines in mammalian cells. Proc. Soc. Exp. Biol. Med. 221:1999;1-13.
42. Perer E.S., Madan A.K., Shurin A., Zakris E., Romeguera K., Pang Y., Beech D.J. Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells. J. Surg. Res. 94:2000;1-5.
43. Frasca F., Pandini G., Scalia P., Sciacca L., Mineo R., Costantino A., Goldfine I.D., Belfiore A., Vigneri R. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol. Cell. Biol. 19:1999;3278-3288.
44. Morrione A., Valentinis B., Xu S.Q., Yumet G., Louvi A., Efstratiadis A., Baserga R. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc. Natl Acad. Sci. USA. 94:1997;3777-3882.